P3MO Ltd (“the Company” or “P3MO”) is an enterprise SaaS platform that simplifies complex modernisation and transformation projects – from multi-million-pound drug approval programmes in pharma to large-scale IT upgrades in government.

• Transformation programmes frequently fail – with over 80% missing their objectives – wasting significant time and resources. Founded by experienced project managers and tech developers, P3MO addresses this problem with a SaaS platform that gives senior executives actionable insights with no extensive training required.
• The global market for enterprise transformation software is valued at more than $550 billion. P3MO is focused on the $5.7 billion project and portfolio management segment, forecast to grow to $12.3 billion by 2030 (14.2% CAGR). P3MO’s target sectors include life sciences, public sector, infrastructure and large industrial corporates.
• P3MO has delivered strong results with multi-national customers including AstraZeneca, where 70+ projects cut governance time by 72%, reduced reporting effort by 90%, and saved $1.2m through the identification of a critical regulatory milestone.
• £1.3m cumulative revenue has been generated from AstraZeneca since 2022. £396k sales are projected for 2025, with £1.4m expected over the next 18 months to reach £1.2m ARR.
• The near-term sales pipeline totals £2.2m, including a major US FMCG, a leading UK BPO/professional services firm, two national park authorities, a housing group, and a global outsourcing brand. A £15m strategic opportunity is also under active development.

• £1.25m (£4.1m Growthdeck pre-fundraise valuation).
• £250k already invested by Fuel Ventures with a further £500k sought from co-investors.
• £500,000 opportunity for Growthdeck Investors (9.57% stake).
• Exit targeted from 2030 at £100m valuation (4x ARR).
• EIS-qualifying.
• Funding will be used to scale rollouts with enterprise customers and enhance product features including AI analytics.